Accord Healthcare Inc, a US-based generic pharmaceutical company, announced on Wednesday that it has added Dehydrated Alcohol Injection to its line of cardiovascular drugs.

Accord's product is AB-rated to BPI Labs' Ablysinol and is offered in 99% 5mL vials.

Dehydrated Alcohol is approved by the FDA and is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy.

"The launch of Accord Healthcare's Dehydrated Alcohol Vials represents a meaningful advancement in offering a more convenient alternative to the traditional ampule market," said Chrys Kokino, Accord Healthcare US president.